RESEARCH ARTICLE

Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the Emergency Department setting

Hollis R. O’Neal, Jr.,1,2 Roya Sheybani,3*, Terrell S. Caffery1,2, Diana Hamer1,2, L. Mark Laperouse, Jr.,2, Mandi W. Musso1,2, Catherine S. O’Neal1,2, Henry T. K. Tse3, Ajay M. Shah3, Christopher B. Thomas1,2

1 Louisiana State University Health Sciences Center, Baton Rouge, Louisiana, United States of America,
2 Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States of America,
3 Cytovale, Inc., San Francisco, California, United States of America

* roya.sheybani@cytovale.com

Abstract

Objective
Assess the IntelliSep Index (ISI) for risk stratification of patients presenting to the Emergency Department (ED) with respiratory symptoms suspected of COVID-19 during the pandemic.

Methods
An observational single-center study of prospective cohort of patients presenting to the ED during the early COVID-19 pandemic with respiratory symptoms and a CBC drawn within 4.5 hours of initial vital signs. A sample of this blood was aliquoted for performance of the ISI, and patients were followed for clinical outcomes. The study required no patient-centered activity beyond standard of care and treating clinicians were unaware of study enrollment and ISI test results.

Main findings
282 patients were included. The ISI ranges 0.1 to 10.0, with three interpretation bands indicating risk of adverse outcome: low (green), 0.1–4.9; intermediate (yellow), 5.0–6.2; and high (red), 6.3–10.0. Of 193 (68.4%) tested for SARS-CoV-2, 96 (49.7%) were positive. The ISI resulted in 182 (64.5%) green, 54 (18.1%) yellow, and 46 (15.6%) red band patients. Green band patients had a 1.1% (n = 2) 3-day mortality, while yellow and red band had 3.7% (n = 2, p > .05) and 10.9% (n = 5, p < .05) 3-day mortalities, respectively. Fewer green band patients required admission (96 [52.7%]) vs yellow (44 [18.1%]) and red (46 [15.6%]) red band patients. Green band patients had a 1.1% (n = 2) 3-day mortality, while yellow and red band had 3.7% (n = 2, p > .05) and 10.9% (n = 5, p < .05) 3-day mortalities, respectively. Fewer green band patients required admission (96 [52.7%]) vs yellow (44 [81.5%]) and red (46 [93.5%]). Green band patients had more hospital free days (median 23 [Q1-Q3 20–25] than yellow (median 22 [Q1-Q3 0–23], p < 0.05) and red (median 21 [Q1-Q3 0–24], p < 0.01). SOFA increased with interpretation band: green (2, [Q1-Q3 0–4]) vs yellow (4, [Q1-Q3 2–5], p < 0.001) and red (5, [Q1-Q3 3–6]) p < 0.001.
Conclusions
The ISI rapidly risk-stratifies patients presenting to the ED during the early COVID-19 pandemic with signs or suspicion of respiratory infection.

Introduction
Emerging and re-emerging pathogens are a persistent threat to the public health [1]; indeed, the COVID-19 pandemic, caused by worldwide circulation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has illustrated this threat. As a result of complex host-pathogen interactions [2], infection with SARS-CoV-2 results in a spectrum of clinical disease with widely variable severity [3–7], from asymptomatic carriage to a dysregulated immune response that leads to organ dysfunction and death [8–11]. No specific clinical features discern COVID-19 from other respiratory illnesses [12]. Throughout this pandemic, as hospitals filled with patients under investigation for COVID-19, clinicians attempted to discern high-risk patients at who need aggressive intervention from lower-risk patients who may benefit from a more conservative approach [13].

Timely recognition of patients with a dysregulated immune response may facilitate decision making and optimize both clinical care and resource utilization [14] in situations where the pathogen is poorly understood or when rapid diagnostic and pathogen identification tests are not available. In these situations, a pathogen-agnostic assessment of the host response may assist clinicians in the risk stratification of persons under investigation for infection by providing a patient-centered, objective assessment of the state of immune activity.

By assessing the biophysical properties of thousands of leukocytes [15, 16], we are able to quantify the state of innate immune activation in the Intellisep Index (ISI) [17], which we have shown to have the potential to be a rapid, reliable diagnostic for sepsis in patients presenting to the emergency department with signs or suspicion of infection [18]. To explore the utility of the ISI in the setting of a pandemic caused by a novel pathogen, we conducted a prospective, observational study of patients presenting to the ED of a large academic medical center with respiratory symptoms early in the COVID-19. Here, we report the performance of this tool as a means to stratify this population for risk of morbidity—especially respiratory—and mortality early in the course of the ED visit, independent of the patient’s SARS-CoV-2 infection status.

Methods
This is an observational single-center, prospective cohort that required no patient-centered activity beyond standard of care. The ISI results were experimental only, and treating clinicians were aware of neither study enrollment nor test results. The Louisiana State University Health Sciences Center Institutional Review Board approved the study protocol and granted waivers of informed consent (Louisiana State University Health Sciences Center–New Orleans, Human Subjects Research Protection Program and Institutional Review Board: LSUHSC-NO #20–048; ClinicalTrials.gov NCT04372472).

Study population and sample collection
During the study period of April 07 through April 28, 2020 Louisiana’s rate of incident SARS-CoV-2 infection was among the highest in the U.S. [19, 20]. We screened 307 adult patients who presented to the ED’s respiratory care unit of Our Lady of the Lake Regional Medical
Center, an 800-bed academic medical center in Baton Rouge, Louisiana. Only patients with a complete blood count (CBC) collected were included in the study. Research staff aliquoted 0.3 to 1.0 milliliters of whole blood from the EDTA-anticoagulated tube (drawn for the CBC) for ISI measurement. The protocol excluded those with an insufficient volume of blood or invalid ISI results. Laboratory technicians completed the test within five hours of venipuncture to avoid possible sample degradation.

IntelliSep test
The IntelliSep test (Cytovale Inc., San Francisco, CA) is an investigational laboratory test conducted on 100 microliter sample of whole blood [17]. It assesses intracellular and nuclear changes that occur during leukocyte activation by measuring the biophysical parameters of tens of thousands of leukocytes in less than 10 minutes. The test provides a single score, the IntelliSep Index (ISI), between 0.1–10.0, (inclusive), stratified into three discrete interpretation bands of risk for morbidity and mortality: green (low-risk, 0.1–4.9), yellow (intermediate-risk, 5.0–6.2), and red (high-risk, 6.3–10.0). The green band includes the 95% Confidence Interval of measurements from healthy donors. The algorithm for calculating the ISI and limits for interpretation bands were defined based on all-cause sepsis-focused studies prior to March 2020 [17]. No information from patients in this study influenced the calculations or interpretation band of the ISI.

Data collection
Study coordinators collected demographic information, baseline data, comorbidities, physiologic data, laboratory values, and need for life support through chart review. Coordinators collected radiographic, historical, physical and laboratory data from the medical record for the identification of specific infections based on pre-defined criteria. In addition, coordinators calculated baseline Sequential Organ Failure Assessment (SOFA) scores [21] and daily SOFA scores for each of the first three days of hospitalization. Other than the ISI, available data were a result of standard care. Details for the calculation of SOFA scores is provided in the S1 File; criteria for assignment of objective infection are modified from the Centers for Disease Control and Prevention’s National Healthcare Safety Network criteria [22]. Calculation of APACHE II is described elsewhere [23].

Statistical analysis
Unless otherwise stated, p-values were obtained from an unpaired two-sample Welch’s t-test or Mann-Whitney U, as appropriate, where the null hypothesis is that the mean of the two samples are equal. Descriptive statistics are presented as means, standard deviations, medians, and interquartile ranges for the continuous variables, and as counts and percentages for categorical variables. An alpha level of 5% is used for all analyses, unless otherwise stated. Two-sided confidence intervals for proportions are provided using the Clopper-Pearson method, where appropriate. Time-to-event analyses are depicted with Kaplan-Meier plots, and the log-rank test was used for comparison between groups.

Results
Table 1 contains baseline characteristics and comparative statistical descriptions for the overall study population and the subsets of patients in the green, yellow and red ISI bands. Coordinators screened 307 eligible patients for the study, and 282 patients had sufficient volume of blood sample and evaluable data to be included in the study (Fig 1). The median age was 61
Table 1. Baseline characteristics and selected outcomes of all evaluable patients (total) as well as stratified by ISI interpretation band.

| Characteristic | Total N = 282 | Green Band N = 182 | Yellow Band N = 54 | Red Band N = 46 | p-value |
|---------------|--------------|--------------------|--------------------|-----------------|---------|
| Age, median (Q1-Q3) | 60.5 (46–73) | 56.5 (46–73) | 65 (51.5–76) | 64.5 (49–76) | * p < 0.05; † p < 0.01 |
| Gender (Female), N (%) | 144 (51.1) | 98 (53.8) | 24 (44.4) | 22 (47.8) | NS |
| Race, N (%) | | | | | |
| White | 114 (40.2) | 68 (37.7) | 21 (38.9) | 25 (54.3) | * p < 0.05 |
| African American | 148 (52.5) | 101 (55.5) | 30 (55.5) | 17 (37.0) | * p < 0.05 |
| Other | 20 (7.1) | 13 (7.1) | 3 (5.6) | 4 (8.7) | |
| Comorbidities (N, %) | | | | | |
| Hypertension | 172 (61) | 106 (58) | 35 (65) | 31 (67) | NS |
| Diabetes | 81 (28.7) | 46 (25.3) | 16 (29.6) | 19 (41.3) | |
| Obesity (BMI >= 30) | 105 (37.2) | 63 (34.6) | 20 (37.0) | 22 (47.8) | |
| Cancer | 33 (11.7) | 21 (11.5) | 7 (13.0) | 5 (10.9) | |
| SARS-CoV-2 Testing (N, %) | | | | | |
| Number Tested | 193 (68.4) | 104 (57.1) | 49 (90.7) | 40 (87.0) | I p < 0.001; H p < 0.001 |
| Number Positive (of tested) | 96 (49.7) | 53 (51.0) | 23 (46.9) | 20 (50.0) | NS |
| Number Positive (of total) | 3 (3.2) | 3 (3.8) | 12 (22.2) | 12 (30.4) | NS |
| Blood Culture (N, %) | | | | | |
| Number Tested | 114 (40.4) | 51 (28.0) | 30 (55.6) | 33 (71.7) | I p < 0.001; H p < 0.001 |
| Number Positive (of tested) | 14 (12.3) | 3 (5.9) | 4 (13.3) | 7 (21.2) | NS |
| Admitted to Hospital (N, %) | 183 (64.9) | 96 (52.7) | 44 (81.5) | 43 (93.5) | I p < 0.001; H p < 0.001 |
| Admitted to ICU (N, %) | 52 (18.4) | 24 (13.2) | 10 (18.5) | 18 (39.1) | I p < 0.01; † p < 0.05 |
| Hospital Free Days (Admitted Subjects), median (Q1-Q3) | 22 (11.5–24) | 23 (20–25) | 21.5 (20–23) | 21 (0–23.5) | I p < 0.01; † p < 0.05 |
| Mortality, N (%) | 9 (3.2) | 2 (1.1) | 2 (3.7) | 5 (10.9) | * p < 0.05 |
| 3-day | 18 (6.4) | 3 (1.6) | 6 (11.1) | 9 (19.6) | * p < 0.05; † p < 0.01 |
| 7-day | 40 (14.2) | 14 (7.7) | 12 (22.2) | 14 (30.4) | * p < 0.05; † p < 0.01 |
| SOFA, 3-day max, median (Q1-Q3) | 3 (1–5) | 2 (0–4) | 4 (2–5) | 4.5 (3–6) | I p < 0.001; H p < 0.001 |
| Maximum SOFA change from enrollment for those admitted, median (Q1-Q3) | 0 (-1–1) | 0 (-1–1) | 0 (-1–2) | 0 (-2–1) | NS |
| APACHE II, median (Q1-Q3) | 11 (6–17) | 9 (4–13) | 14 (9–18) | 14 (11–19) | I p < 0.001; H p < 0.001 |
| P/F ratio, 3-day min, median (Q1-Q3) | 295 (189–414) | 329 (221–457) | 262 (158–321) | 218 (151–304) | I p < 0.001; H p < 0.001 |
| WBC (10⁹ cells/L), median (Q1-Q3) | 8.2 (5.9–11.9) | 7.3 (5.6–10.3) | 9.6 (7.0–12.7) | 11.9 (7.0–18.0) | H p < 0.01; † p < 0.001 |
| Segmented Neutrophils (%), median (Q1-Q3) | 74 (64–82) | 69 (59–77) | 80 (78–86) | 82 (76–88) | I p < 0.001; H p < 0.001 |
| Lymphocytes (%), median (Q1-Q3) | 17 (10–26) | 23 (16–30) | 11 (7–15) | 8 (6–13) | I p < 0.001; H p < 0.001 |
| Monocytes (%), median (Q1-Q3) | 6 (4–9) | 6 (5–9) | 6 (4–9) | 6 (4–8) | NS |
| Platelets (10⁹ cells/L), median (Q1-Q3) | 230 (172–294) | 229 (175–288) | 223 (159–271) | 243 (163–330) | NS |
| Blood Urea Nitrogen (mg/dL), median (Q1-Q3) | 16 (11–28) | 14 (10–22) | 28 (14–52) | 20 (14–33) | * p < 0.05; † p < 0.001 |
| Creatinine (mg/dL), median (Q1-Q3) | 1.10 (0.81–1.55) | 1.01 (0.79–1.32) | 1.53 (1.06–2.86) | 1.13 (0.96–1.99) | NS |
| Triage Temperature (F), median (Q1-Q3) | 98.7 (98.0–99.7) | 98.5 (98.0–99.3) | 99.2 (98.0–100.1) | 99.1 (98.0–101.0) | I p < 0.01 |

(Continued)
years, 138 (49%) were men, 114 (40%) were white, 148 (52%) were black, and 20 (7%) were members of other races. In total, 149 patients (53%) met at least one objective infection criteria, including 110 (39%) respiratory, 30 (11%) urinary, and 20 (7%) gastrointestinal infections. Comorbidities included 172 (61%) hypertension, 81 (29%) diabetes, 105 (37%) obesity, and 33 (12%) cancer.

Of the 282 patients in the overall study population, clinicians tested 193 (68%) for SARS-CoV-2 infection shortly prior to or during the ED encounter or associated admission, and 96 (34% of total, 50% of tested) were positive. In the majority of cases, the ED clinicians were unaware of SARS-CoV-2 infection status, as molecular diagnostics at the time of enrollment resulted at least 24 hours after collection (a minority of patients tested positive prior to the ED counter associated with enrollment). A total of 183 (65%) patients were admitted to the hospital with a median length of stay of 5 days, and 52 (18%) were admitted to the Intensive Care Unit (ICU). Forty (14% of total, 22% of admitted) patients died while in the hospital.

The median baseline SOFA score of all patients was 0 (Q1-Q3, 0–1). The median SOFA score for all patients was 2 on Day 1 (Q1-Q3, 1–4), 3 on Day 2 (Q1-Q3, 2–5), and 2 on Day 3 (Q1-Q3, 2–4). The median APACHE-II score for all patients, calculated from the worst values in the date of the ED encounter, was 11 (Q1-Q3, 6–17).

The median ISI for all patients was 4.2. Using prespecified cutoffs for ISI, 182 (64%) were classified as green, 54 (19%) yellow, and 46 (16%) red. The red band had a median age of 64.5 years and included a higher percentage of white patients (54.3%). By comparison, the green band had a median age of 56.5 (p < .05) and included a higher percentage of black patients (55.5%, p < 0.05). The red band also had higher percentages of patients who were diabetic (41.3%) or obese (47.8%), as compared to the green (25.3% diabetic, p > 0.05 and 34.6% obese, p > 0.05).

Patients with SARS-CoV-2 infection had baseline demographics similar to the overall study population, both in total and when stratified by ISI risk category (Table 2). Of the 96 patients who tested positive for SARS-CoV-2 infection, 53 (55%) were classified into the green band, 23 (24%) yellow, and 20 (21%) red.

### Mortality

Fig 2 depicts Kaplan-Meier survival curves stratified by ISI risk group. Among the 282 patients in the overall study population, the green band (n = 182) had a 3-day mortality of 1.1% and 7-day mortality of 1.6%, while the yellow band (n = 54) had a 3-day mortality of 3.7% and 7-day mortality of 11.1%, and the red band (n = 46) had a 3-day mortality of 10.9% and 7-day mortality of 19.6% (Fig 2A). Among the 96 patients that tested positive for SARS-CoV-2, those classified as green (n = 53) had a 3-day mortality of 0.0% and 7-day mortality of 1.9%, while patients classified as yellow (n = 23) had a 3-day mortality of 4.3% and 7-day mortality of 8.7%, and patients classified as red (n = 20) had a 3-day mortality of 15.0% and 7-day mortality of 19.6% (Fig 2B).
Fig 1. 307 adult patients with suspicion of respiratory infection for which a complete blood count was ordered in the emergency department were screened, 7 subjects met exclusion criteria for insufficient sample quantity and were not enrolled, 1 subject was enrolled repeatedly, and the second enrollment was excluded. Due to user error, test data was not recorded for 10 subjects and for 6 subject samples, testing did not produce a valid ISI. As a result, 282 subjects were included in the study analysis.

https://doi.org/10.1371/journal.pone.0264220.g001

of 35.0% (Fig 2B). These survival trends continue, with only 55% of those in the red band surviving at 15 days, compared to 87% of those in the green band. Of the remaining 186 patients, who were either not tested or were negative for SARS-CoV-2, 129 were in the green band with a 3-day mortality of 1.6% and 7-day mortality of 1.6%; 31 were in the yellow band with a 3-day
| Characteristic | Total N = 96 | Green Band N = 53 | Yellow Band N = 23 | Red Band N = 20 | p-value |
|---------------|-------------|------------------|------------------|----------------|---------|
| Age, median (Q1-Q3) | 65 (51–75) | 61 (47–73) | 65 (52–69) | 70 (58–80) | NS |
| Gender, N (%) | | | | | |
| Female | 46 (47.9) | 29 (54.7) | 8 (34.8) | 9 (45.0) | NS |
| Male | 50 (52.1) | 24 (45.3) | 15 (65.2) | 11 (55.0) | |
| Race, N (%) | | | | | |
| White | 30 (31.3) | 15 (28.3) | 4 (17.4) | 11 (55.0) | * p < 0.05 |
| African American | 57 (59.4) | 32 (60.4) | 18 (78.3) | 7 (35.0) | t p < 0.05 |
| Other | 9 (9.4) | 6 (11.3) | 1 (4.3) | 2 (10.0) | H p < 0.01 |
| Comorbidities (N, %) | | | | | |
| Hypertension | 67 (69.8) | 33 (62.3) | 18 (78.3) | 16 (80.0) | NS |
| Diabetes | 38 (42.2) | 17 (36.2) | 10 (43.5) | 11 (55.0) | |
| Obesity (BMI 30–39.9) | 33 (34.4) | 20 (37.7) | 6 (26.1) | 7 (35.0) | |
| Obesity (BMI 40–49.9) | 7 (7.3) | 3 (5.7) | 2 (8.7) | 2 (10.0) | |
| Obesity (BMI ≥ 50) | 2 (2.1) | 1 (1.9) | 0 (0.0) | 1 (5.0) | |
| Cancer | 7 (7.3) | 4 (7.5) | 2 (8.7) | 1 (5.0) | |
| Infected—Meeting Objective Criteria (N, %), by organ system: | | | | | |
| Respiratory | 63 (65.6) | 31 (58.5) * | 15 (65.2) | 17 (85.0) * | * p < 0.05 |
| Gastrointestinal | 3 (3.1) | 3 (5.7) | 0 (0.0) | 0 (0.0) | |
| Urinary | 9 (9.4) | 3 (5.7) | 1 (4.3) | 5 (25.0) | |
| Other | 1 (1.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) | |
| Not Infected | 27 (28.1) | 17 (32.1) | 8 (34.8) | 2 (10.0) | * p < 0.05 |
| Blood Culture (N, %) | | | | | |
| Number Tested | 46 (47.9) | 21 (39.6) | 11 (47.8) | 14 (70.0) | NS |
| Number Positive (of tested) | 1 (2.2) | 1 (4.8) | 0 (0.0) | 0 (0.0) | NS |
| Admitted to Hospital (N, %) | 79 (82.3) | 40 (75.5) H | 19 (82.6) H | 20 (100.0) H | t p < 0.05 |
| Admitted to ICU (N, %) | 20 (20.8) | 8 (15.1) | 4 (17.4) | 8 (40.0) | NS |
| Hospital Free Days (Admitted Subjects), median (Q1-Q3) | 21 (0–24) | 21 (10–24) | 23 (6–24) | 21 (0–23) | NS |
| Mortality, N (%) | 3-day | 4 (4.2) | 0 (0.0) | 1 (4.3) | 3 (15.0) | NS |
| 7-day | 10 (10.4) | 1 (1.9) * | 2 (8.7) H | 7 (35.0) * H | * p < 0.01 |
| In-hospital | 24 (25.0) | 9 (17.0) * | 6 (26.1) | 9 (45.0) * | * p < 0.05 |
| SOFA, 3-day max, median (Q1-Q3) | 3 (2–5) | 3 (1–4) * | 4 (3–5) | 3 (2–7) | * p < 0.05 |
| Maximum SOFA change from enrollment for those admitted, median (Q1-Q3) | 0 (1–1) | -1 (-2–1) | -1 (-2–1) | 0 (-1–1) | NS |
| APACHE II, median (Q1-Q3) | 13 (7–17) | 11 (4–14) H | 15 (11–18) H | 17 (13–20) H | t p < 0.001 |
| P/F ratio, 3-day min, median (Q1-Q3) | 246 (152–329) | 261 (164–329) | 243 (150–303) | 183 (114–310) | NS |
| WBC (10³ cells/μL), median (Q1-Q3) | 7.0 (5.4–9.5) | 6.0 (5.2–7.9) H | 7.8 (6.6–10.3) | 7.2 (6.0–13.8) | t p < 0.05 |
| Segmented Neutrophils (%), median (Q1-Q3) | 74 (67–80) | 69 (58–77) * H | 79 (73–82) * H | 80 (74–85) H | * p < 0.001 |
| Lymphocytes (%), median (Q1-Q3) | 17 (11–24) | 23 (15–31) H | 12 (10–17) H | 12 (7–15) H | t p < 0.001 |
| Monocytes (%), median (Q1-Q3) | 6 (4–9) | 6 (4–8) | 6 (4–9) | 6 (4–8) | NS |
| Platelets (10³ cells/μL), median (Q1-Q3) | 191 (152–256) | 197 (147–256) | 185 (154–243) | 189 (154–261) | NS |
| Blood Urea Nitrogen (mg/dl), median (Q1-Q3) | 21 (13–35) | 18 (11–26) * | 30 (15–49) * | 26 (14–34) | * p < 0.05 |
| Creatinine (mg/dl), median (Q1-Q3) | 1.2 (0.8–1.9) | 1.1 (0.8–1.4) * | 1.8 (1.3–2.9) | 1.2 (0.9–2.1) | * p < 0.05 |
| Triage Temperature, median (Q1-Q3) | 99.1 (98.5–100.2) | 99.1 (98.5–100.0) | 99.5 (98.7–100.5) | 99.0 (98.0–100.1) | NS |

(Continued)
mortality of 3.2% and 7-day mortality of 12.9%; 26 were in the red band with a 3-day mortality of 7.7% and 7-day mortality of 7.7% (Fig 2C).

**Severity of illness and utilization of hospital resources**

**Fig 3** depicts severity of illness scores and hospital resource utilization for the overall study population, stratified by ISI group. ISI categories were consistent with severity of illness as measured by three-day maximum SOFA scores (Fig 3A). Patients in the red band had higher three-day maximum SOFA scores (median 5, Q1-Q3 = 3–6) than the green band (median 2, Q1-Q3 = 0–4) (p < 0.001). There was also a significant difference in three-day maximum SOFA scores between yellow (median 4, Q1-Q3 = 2–5) and green band patients (median 2, Q1-Q3 = 0–4) (p<0.001). There was no significant difference in three-day maximum SOFA scores between the red (median 5, Q1-Q3 = 3–6) and yellow patient groups (median 4, Q1-Q3 = 2–5) (p>0.05). Among admitted patients, those in the red band were more likely to have an increase in SOFA scores in second and third days of hospitalization compared to green band patients, who were more likely to have a decrease in SOFA scores during this time (Fig 3B).

ISI risk categories were also consistent with severity of illness as measured by APACHE-II (Fig 3C). Green band patients had a median APACHE-II score of 9 (Q1-Q3 = 4–13), while yellow band patients had a median score of 14 (Q1-Q3 = 9–18, p < 0.001), red band patients had a median score of 14 (Q1-Q3 = 11–19, p<0.001). Additionally, red band patients were more likely to test positive for pathogens. Blood cultures were drawn for 33 red band patients, of which 7 (21% of tested) were positive, 30 yellow band patients of which 4 (13% of tested) were positive, and 51 green band patients of which 3 (6%) were positive (Table 1).

Differences in the utilization of hospital resources were also observed between interpretation bands. Hospital admissions were lowest for green band patients, with ED clinicians admitting 96 (53%) green band patients, 44 (82%) yellow band patients, and 43 (94%) red band patients (Fig 3D). Rates of admission to the intensive care unit (ICU) showed similar trends (Fig 3E), with red band patients more likely to require admission to the ICU (39%) compared to yellow band (19%, p < 0.05) and green band patients (13%, p < 0.01). Among those admitted to the hospital, green band patients had more hospital-free days (median 23, Q1-Q3 = 20–25) than yellow band (median 22, Q1-Q3 = 0–23) (p < 0.05) and red band patients (median 21, Q1-Q3 = 0–24) (p < 0.01) (Fig 3F).

Clinical trends observed for the ISI risk categories for the subset of patients that tested positive for SARS-CoV-2 (n = 96, 34% of study population) were consistent with the overall population (Fig 4). As compared to green band patients, red and yellow band patients had higher APACHE II and three-day maximum SOFA scores. Among those admitted to the hospital, red
band and yellow band patients were more likely to have an increase in SOFA scores in second and third days of hospitalization. Red band patients also had higher rates of hospital and ICU admissions and, among those admitted to the hospital, fewer hospital-free days than those in the green band.

**Need for life support**

Patients with higher ISI scores were also more likely to require life support, including advanced oxygen-delivery and vasopressor support, in the first three days of hospitalization.
Because of variability throughout the study period in the utilization of mechanical ventilators for SARS-CoV-2 positive patients, we defined the need for advanced oxygen-delivery as patients with a PaO\(_2\) / FiO\(_2\) ratio of less than 250. Additionally, to delineate a more severely-ill population, we also performed analysis for patients with a PaO\(_2\) / FiO\(_2\) ratio of less than 200. It is important to note, that in the calculation of PaO\(_2\) / FiO\(_2\) ratios, most FiO\(_2\) were estimated from flow rates on high-flow nasal cannula, with considerable variability between providers.

Of patients in the green band, 32% had a minimum PaO\(_2\) / FiO\(_2\) ratio of less than 250 as opposed to 65% in the red band (p < 0.001). Additionally, 20% in the green band had a PaO\(_2\) / FiO\(_2\) ratio of less than 200 while 44% in the red band had a PaO\(_2\) / FiO\(_2\) ratio of less than 200 (p < 0.001). These observations were consistent in the entire study population as well as the population of patients who tested positive for SARS-CoV-2, albeit not statistically significant due to small sample size (S1 Fig in S1 File). Patients in the red band were also more likely to require vasopressor use than patients in the green band in both the entire population (Fig 5B) and in those testing positive for SARS-CoV-2 (S1B Fig in S1 File).

**Discussion**

Patients often present to the ED with undifferentiated illneses, forcing clinicians to make rapid, impactful decisions with limited data and prior to making the definitive diagnosis. As the early period of the COVID-19 pandemic demonstrated, the ED response is further
complicated when the predominant pathogen is novel and poorly understood [6, 7, 24]. As with many infectious diseases, clinical risk factors and biomarkers were found to be associated with adverse outcomes in patients with COVID-19 [25–35]; however, there was no standardized process for interpreting these measures into clinically actionable results. As the pandemic progressed, COVID-19 specific scoring systems for predicting disease severity and mortality were developed, but they required numerous data inputs and observations for calculation which are not available early in the ED course [36–38]. An objective, standardized, rapid pre-diagnostic risk stratification system to aid ED clinicians in discerning patients in immediate jeopardy from those at lower risk could help maintain throughput without sacrificing quality of care in the setting of a novel pathogen [39]. Also, identification of patients with dysregulated immunity may improve allocation of resources, administration of specific interventions, and enrollment in clinical trials as understanding of the pathogen and resultant disease evolve.

Our findings support the potential for the ISI as an aid for early risk stratification of patients presenting to the ED with respiratory complaints early in a pandemic caused by a novel respiratory virus. Importantly, we developed the ISI using a model developed on an unrelated cohort of patients with signs or suspicion of infection that predated the COVID-19 pandemic [17], illustrating its versatility in the risk stratification of infection by a variety of pathogens. In the current study, red band patients experienced a 3-day mortality of 10.9%, nearly 10-times higher than that of green band patients. Furthermore, the mortality of red band patients.

Fig 4. Trends in severity of illness scores and hospital utilization across ISI interpretation bands for SARS-CoV-2 positive subjects. (A) SOFA scores, maximum calculated over up to 3-days with the subject’s baseline over the prior 6-months subtracted; (B) maximum SOFA change over 3-days from day of presentation; (C) APACHE II scores calculated using worse values over 24 hours following presentation; (D) hospital admission; (E) admission to the ICU; (F) hospital-free days in those admitted to the hospital, calculated as 28 – hospital length of stay, with zero for in-hospital mortality. Box plots: lines in the boxes, medians; the box ends, interquartile ranges (IQR); whiskers, 1.5x IQR; diamonds, outliers. Bar graphs: Bars, percentages; error bars, 95% confidence intervals. p-values were obtained from an unpaired two-sample Welch’s t-test (except for hospital-free days, where the Mann–Whitney U was due to the non-normal distribution), with the null hypothesis that the mean of the two samples are equal. p-values reported as *p < 0.05, **p < 0.01, and ***p < 0.001.

https://doi.org/10.1371/journal.pone.0264220.g004
remained higher at 7-days in both the total population and amongst those with SARS-CoV-2 infection (Fig 2, Table 1). These findings suggest that ED clinicians should evaluate this population with urgency and consideration for movement to a high level of care. While ED clinicians admitted 93.5% of red band patients, including 39.1% to the ICU (Fig 3D and 3E), they also expressed concern for deterioration of patients in the green band, admitting 52.7% in total, including 13.2% to the ICU. The median length of stay for these low-risk patients was comparatively short, as indicated by the high number hospital-free days. In appropriate situations, green band patients may benefit from admission to low-acuity units or outpatient monitoring [13] with close follow-up. Since the numbers of green band patients admitted (n = 96)

Fig 5. Trends in the need for life support (advanced oxygen-delivery and vasopressor support) across ISI interpretation bands for all subjects. (A) Minimum PaO2 / FiO2 ratio over up to 3-days, (B) need for vasopressors over up to 3-days; (C) minimum PaO2 / FiO2 ratio of less than 250 over up to 3-days; (D) minimum PaO2 / FiO2 ratio of less than 200 over up to 3-days. Box plots: lines in the boxes, medians; the box ends, interquartile ranges (IQR); whiskers, 1.5x IQR; diamonds, outliers. Bar graphs: Bars, percentages; error pars, 95% confidence intervals. p-values were obtained from an unpaired two-sample Welch’s t-test, with the null hypothesis that the mean of the two samples are equal. p-values reported as * p < 0.05, ** p < 0.01, and *** p < 0.001.

https://doi.org/10.1371/journal.pone.0264220.g005
was higher than the number of red (n = 46) and yellow (n = 43) band patients admitted combined, it appears that the test has the potential to conserve a meaningful amount of physical and personnel resources.

In addition to risk stratification for mortality and hospitalization, the ISI reflects the patients’ clinical courses with respect to complex, well-validated severity of illness scores. Because clinical indicators of organ dysfunction lag behind the underlying biologic process [40–42], we assessed the ISI compared to the maximum SOFA score over the first three days of hospitalization as well as APACHE II scores. The ISI results within minutes of presentation, and it was consistent with scoring systems (Fig 3A and 3C) that require cumulative laboratory and physiologic data captured over several hours to days. Finally, the ISI also identifies a population of patients who may exhibit improvement within the first 3 hospital days (Fig 3B), which could facilitate case management and discharge planning [43].

Importantly, the ISI risk stratifies patients with SARS-CoV-2 infection with the same degree of precision as other patients included in the study. As an assay for the host response, the ISI is a means of quantifying the state of immune activation. Since dysregulated immunity leads to organ dysfunction in severely affected patients, any pathogen causing dysregulated immune response will yield an elevated score [17]. Although we conducted this study primarily in the respiratory care unit of an ED in a high-prevalence area for SARS-CoV-2, as the study was performed prior to the availability of rapid and routine COVID-19 testing, the majority of patients enrolled (66.0%) were either not tested for SARS-CoV-2 or tested negative. This finding is reflective of the uncertainty in practicing Emergency Medicine during a pandemic caused by a novel, poorly-understood pathogen. Nonetheless, among patients testing positive for the novel pathogen, the ISI risk stratification was consistent with SOFA and APACHE II scores and reflected the greater need of high-risk patients for hospitalization and intensive care (Fig 4) independent of the pathogen detection. These findings imply that the ISI can assist ED clinicians in the risk stratification and direction of care for patients before the results of diagnostic tests are available. Furthermore, because the ISI has a rapid turnaround time, it can assist ED clinicians in allocating diagnostics, reserving the more rapid and often scarce tests for those in whom rapid pathogen detection is most critical.

The ISI is a measure of innate immune activity [15–17]. As a result, processes that lead to morbidity or mortality by alternative mechanisms may not result in higher scores. This is apparent in the two green band patients who died in the first three days—one experienced out-of-hospital cardiac arrest and the other a drug overdose. The ISI result was consistent with the fact that neither death was caused by immune dysfunction. Also, patients who present early in the course of infection, prior to the development of immune dysfunction, may be classified into the green band. In these cases, repeated testing may indicate developing immune dysregulation that was not evident initially. Finally, because the ISI quantifies structural changes of leukocytes, conditions known to impact leukocyte structure (e.g., hematologic malignancies, cytotoxic chemotherapy) may impact ISI results.

Our study has several limitations. Though the patient population is diverse and the enrollment pragmatic, it is unclear if the findings of this exploratory single-center study will generalize to other institutions or patient populations. Also, our study was conducted early in the pandemic when infection control concerns limited research staff, so we used remnant blood from patients who had a CBC performed for standard of care for ISI measurement; thus, we were unable to uniformly assess the ISI against commonly measured biomarkers. The study population has a significant representation of black and white patients but does not have significant representation of Hispanic or Asian patients. Because enrollment required a CBC, some degree of risk stratification by the attending providers existed prior to enrollment. Additionally, this study evaluates a single ISI measurement early in the ED course, so we are unable
to assess how the ISI trends with progression or resolution of illness. Finally, at the time of enrollment, there was no standardized treatment of COVID-19, so the outcomes may be more representative of the natural course of the disease rather than the current state of treatment.

**Conclusion**

The ISI is a pathogen-agnostic, quantitative measure of immune activation; in patients with suspected infection, elevated scores indicate a state of immune dysregulation and portend an immediate risk of adverse outcomes while lower scores portend a less-severe course. As evidenced by its performance during the early COVID-19 pandemic, the ISI may improve efficiency in resource allocation by offering rapid pre-diagnostic risk stratification of patients with suspected infection, independent of the pathogen. This finding is especially important in times of increased ED volumes, prolonged wait times, and diagnostic test delays that are found in a pandemic caused by a novel and evolving pathogen such as SARS-CoV-2. As our understanding of the pathogen and resultant illness evolves, the ISI may help stratify patients for potential interventions. In less than ten minutes and using 100 microliters of whole blood, the ISI has the potential to provide reliable prognostic information that currently requires hours or days to accumulate. In the future, the ISI may provide useful diagnostic and prognostic information for patients with suspected infection and possible immune dysregulation that can lead to life-threatening organ dysfunction.

**Supporting information**

S1 Checklist. CONSORT 2010 checklist of information to include when reporting a randomised trial.

(PDF)

S1 File. Additional figure on Trends in the need for life support (advanced oxygen-delivery and vasopressor support) across ISI interpretation bands for SARS-CoV-2 positive subjects. SOFA (Sequential [Sepsis-Related] Organ Failure Assessment) Score Calculation Procedure.

(DOCX)

S1 Dataset. Spreadsheet including all data pertaining to the clinical characteristics, ISIs, and interpretation bands per subject.

(CSV)

**Acknowledgments**

The authors would like to express their gratitude to the Office of Research at Our Lady of the Lake Regional Medical Center and the personnel who worked tirelessly to screen and enroll patients: Katie Vance, PhD; Jennifer Daigle, BSN; JoAnne Hollingsworth, BSN; Brittany Rishell, BSN; Emily Perdue, RN; Gretchen Figarola, BSN; Julie Doyle, LPN; Becky Toler BSN; Anne Erwin, MSN; Allie Piehet, BS; and Tina Martinez. In addition, the authors would like to recognize Claire Alexander BSN, MBA; Annie Jensen; Alex Malkin PhD; and Hunter Stevenson, PhD at Cytovale for their heroic efforts setting up and operating this study during the early stages of the COVID-19 Pandemic. Lastly, the authors would like to thank Lionel Guillou, PhD and Linda Kahl, PhD for their help in completing this study and manuscript.

**Author Contributions**

Conceptualization: Hollis R. O’Neal, Jr., Henry T. K. Tse, Ajay M. Shah.
Data curation: Roya Sheybani.

Formal analysis: Roya Sheybani.

Funding acquisition: Henry T. K. Tse, Ajay M. Shah.

Investigation: Hollis R. O’Neal, Jr., Roya Sheybani, Terrell S. Caffery, Diana Hamer, L. Mark Laperouse, Jr., Mandi W. Musso, Catherine S. O’Neal, Christopher B. Thomas.

Methodology: Hollis R. O’Neal, Jr., Henry T. K. Tse, Ajay M. Shah, Christopher B. Thomas.

Project administration: Hollis R. O’Neal, Jr., Henry T. K. Tse, Ajay M. Shah.

Software: Roya Sheybani.

Supervision: Hollis R. O’Neal, Jr., Henry T. K. Tse, Ajay M. Shah.

Visualization: Roya Sheybani.

Writing – original draft: Hollis R. O’Neal, Jr., Roya Sheybani.

Writing – review & editing: Hollis R. O’Neal, Jr., Roya Sheybani, Terrell S. Caffery, Diana Hamer, L. Mark Laperouse, Jr., Mandi W. Musso, Catherine S. O’Neal, Henry T. K. Tse, Ajay M. Shah, Christopher B. Thomas.

References
1. Gao GF. From "A"IV to "Z"IKV: Attacks from Emerging and Re-emerging Pathogens. Cell 2018; 172: 1157–1159. https://doi.org/10.1016/j.cell.2018.02.025 PMID: 29522735
2. Varghese PM, Tsokali AG, Yasmin H, Shastrī A, Ferluga J, Vatish M, et al. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology 2020; 225: 152008. https://doi.org/10.1016/j.imbio.2020.152008 PMID: 33130519
3. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 458–464. https://doi.org/10.15585/mmwr.mm6915e3 PMID: 32298251
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264
5. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020; 115: 766–773. https://doi.org/10.14309/ajg.0000000000000620 PMID: 32287140
6. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966. https://doi.org/10.1136/bmj.m1966 PMID: 32443866
7. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382: 1708–1720. https://doi.org/10.1056/NEJMoaa2002032 PMID: 32109013
8. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 2020; 217. https://doi.org/10.1084/jem.20200652 PMID: 32302401
9. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa248 PMID: 32161940
10. Tay MZ, Poh CM, Renia L, MacAny PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20: 363–374. https://doi.org/10.1038/s41577-020-0311-8 PMID: 32346093
11. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420–422. https://doi.org/10.1016/S2213-2600(20)30076-X PMID: 32085846
12. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog 2020; 16: e1008536. https://doi.org/10.1371/journal.ppat.1008536 PMID: 32442210

13. Luks AM, Swenson ER. Pulse Oximetry for Monitoring Patients with COVID-19 at Home: Potential Pitfalls and Practical Guidance. Am Ann Thorac Soc 2020. https://doi.org/10.1513/AnnalsATS.202005-418FR PMID: 32511167

14. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395: 1517–1520. https://doi.org/10.1016/S0140-6736(20)30920-X PMID: 32311318

15. Gossett DR, Tse HT, Lee SA, Ying Y, Lindgren AG, Yang OO, et al. Hydrodynamic stretching of single cells for large population mechanical phenotyping. Proc Natl Acad Sci U S A 2012; 109: 7630–7635. https://doi.org/10.1073/pnas.1200107109 PMID: 22547795

16. Crawford K, DeWitt A, Brierre S, Caffery T, Jagneaux T, Thomas C, et al. Rapid Biophysical Analysis of Host Immune Cell Variations Associated with Sepsis. Am J Respir Crit Care Med 2018; 198: 280–282. https://doi.org/10.1164/rccm.201710-2077LE PMID: 29630392

17. Guillou L, Sheybani R, Jensen AE, Di Carlo D, Caffery TS, Thomas CB, et al. Development and validation of a cellular host response test as an early diagnostic for sepsis. PLoS One 2021; 16: e0246980. https://doi.org/10.1371/journal.pone.0246980 PMID: 33857126

18. O’Neal HR Jr., Sheybani R, Caffery TS, Musso MW, Hamer D, Alwood SM, et al. Assessment of a Cellular Host Response Test as an Sepsis Diagnostic for Those With Suspected Infection in the Emergency Department. Crit Care Explor 2021; 3: e0460. https://doi.org/10.1097/CCE.0000000000000460 PMID: 34151282

19. CDC. CDC COVID-19 Data Tracker. 2020 June 24, 2020. Available from: https://www.cdc.gov/covid-data-tracker/.

20. Wissel BD, Van Camp PJ, Kouril M, Weis C, Glauser TA, White PS, et al. An Interactive Online Dashboard for Tracking COVID-19 in U.S. Counties, Cities, and States in Real Time. J Am Med Inform Assoc 2020.

21. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 2009; 37: 1649–1654. https://doi.org/10.1097/CCM.0b013e3181def97 PMID: 19325482

22. Centers for Disease Control and Prevention, National Healthcare Safety Network. CDC/NHSN Surveillance Definitions for Specific Types of Infections; January 2020.

23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–829. PMID: 3928249

24. Cao Y, Li Q, Chen J, Guo X, Miao C, Yang H, et al. Hospital Emergency Management Plan During the COVID-19 Epidemic. Acad Emerg Med 2020; 27: 309–311. https://doi.org/10.1111/acem.13951 PMID: 32124506

25. Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19): A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China. Clin Infect Dis 2020.

26. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta 2020; 505: 190–191. https://doi.org/10.1016/j.cca.2020.03.004 PMID: 32145275

27. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020; 127: 104370. https://doi.org/10.1016/j.jcv.2020.104370 PMID: 32443321

28. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, et al. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thromb Res 2020; 192: 3–8. https://doi.org/10.1016/j.thromres.2020.05.006 PMID: 32407937

29. Henry BM, de Oliveira MHS, Benoit S, Piebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020; 58: 1021–1028. https://doi.org/10.1515/clcm-2020-0369 PMID: 32286245

30. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis 2020; 95: 304–307. https://doi.org/10.1016/j.ijid.2020.04.061 PMID: 32340111

31. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020; 5.

32. CDC COVID-Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019—United States, February 12-March 28,
33. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 759–765. https://doi.org/10.15585/mmwr.mm6924e2 PMID: 32555134

34. Van Singer M, Brahier T, Ngai M, Wright J, Weckman AM, Eri C, et al. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. J Allergy Clin Immunol 2020. https://doi.org/10.1016/j.jaci.2020.10.001 PMID: 33045281

35. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol 2020; 92: 2409–2411. https://doi.org/10.1002/jmv.26097 PMID: 32516845

36. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa414 PMID: 32271369

37. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. China Medical Treatment Expert Group for C. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med 2020.

38. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease 2019. Crit Care Med 2020. https://doi.org/10.1097/CCM.0000000000004411 PMID: 32697506

39. World Health Organization. Clinical Management of COVID-19: Interim guidance, 27 May; 2020.

40. Aydemir H, Piskin N, Akduman D, Kokturk F, Aktas E. Platelet and mean platelet volume kinetics in adult patients with sepsis. Platelets 2015; 26: 331–335. https://doi.org/10.3109/09537104.2012.701027 PMID: 22731700

41. Nesseler N, Launey Y, Aninat C, Morel F, Malledant Y, Seguin P. Clinical review: The liver in sepsis. Crit Care 2012; 16: 235. https://doi.org/10.1186/cc11381 PMID: 23134597

42. Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2008; 20: 672–679. https://doi.org/10.1681/ASN.2008070669 PMID: 19244578

43. Moreno R, Vincent JL, Matos R, Mendonca A, Cartraire F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 1999; 25: 686–696. https://doi.org/10.1007/s001340050931 PMID: 10470572